Cargando…

Predictive markers of endocrine response in breast cancer

Ongoing clinical and research efforts seek to optimise the use of endocrine therapy in the treatment of breast cancer. Accurate biomarkers are needed that predict response for individual patients. The presence of the estrogen receptor (ER) as the direct (for tamoxifen and fulvestrant) or indirect (f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosly, Duniya, Turnbull, Arran, Sims, Andrew, Ward, Carol, Langdon, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125140/ https://www.ncbi.nlm.nih.gov/pubmed/30191138 http://dx.doi.org/10.5493/wjem.v8.i1.1

Ejemplares similares

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
por: Jarman, Edward J., et al.
Publicado: (2019)

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models
por: Xintaropoulou, Chrysi, et al.
Publicado: (2015)

Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer
por: Huang, Rui, et al.
Publicado: (2014)

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer
por: Bownes, Richard J., et al.
Publicado: (2019)

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers
por: Selli, Cigdem, et al.
Publicado: (2016)

Development and characterisation of acquired radioresistant breast cancer cell lines
por: Gray, Mark, et al.
Publicado: (2019)

Pre-operative Endocrine Therapy
por: Arthur, Laura M., et al.
Publicado: (2017)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Breast density predicts endocrine treatment outcome in the adjuvant setting
por: Cuzick, Jack
Publicado: (2012)

Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer
por: Meehan, James, et al.
Publicado: (2020)

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
por: Xintaropoulou, Chrysi, et al.
Publicado: (2018)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells
por: Meehan, James, et al.
Publicado: (2017)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

Breast cancer: further metabolic-endocrine risk markers?
por: Stoll, B. A.
Publicado: (1997)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Estrogen Receptor Signaling in Cancer
por: Langdon, Simon P.
Publicado: (2020)

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer
por: Kay, Charlene, et al.
Publicado: (2023)

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers
por: Briffa, Romina, et al.
Publicado: (2015)

The Impact of Endocrine Disruptors on Endocrine Targets
por: Gregoraszczuk, Ewa L., et al.
Publicado: (2013)

Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?
por: Fardell, Joanna E, et al.
Publicado: (2023)

Do classical oestrogen markers predict for clinical response to endocrine therapy?
por: Miller, William R
Publicado: (2007)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress
por: Ganz, Patricia A
Publicado: (2016)

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated NDRG1-Driven Proliferation in Triple-Negative Breast Cancer
por: Mishra, Akanksha, et al.
Publicado: (2020)

Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients
por: Lundin, K B, et al.
Publicado: (2011)

S100β as a serum marker in endocrine resistant breast cancer
por: Charmsaz, Sara, et al.
Publicado: (2017)

Hijacking of Endocrine and Metabolic Regulation in Cancer and Diabetes
por: McGowan, Eileen M., et al.
Publicado: (2015)

Thyroid cancer in the era of endocrine disrupting compounds
por: Preda, Cristina
Publicado: (2021)

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
por: Bonello, Maria, et al.
Publicado: (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Endocrine therapy: defining the path of least resistance
por: Stone, Andrew, et al.
Publicado: (2014)

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours
por: Selli, Cigdem, et al.
Publicado: (2019)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness
por: Ward, Carol, et al.
Publicado: (2018)

TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer
por: May, Felicity E B, et al.
Publicado: (2015)

DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.
por: Baildam, A. D., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_gmblsu2ddp5rnbs4foh88ah8vd